Skip to main content

Advertisement

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy

Background

Failure to efficiently degrade the DNA of apoptotic cells activates innate immunity causing chronic arthritis. If deficient, Dnase I could lead to accumulation of undigested DNA which induce activation of phagocytes and production of proinflammatory cytokines, notably TNF.

Methods

The study was performed in 25 JIA patients who donated paired serum samples prior and one year after continous etanercept therapy. Basic clinical data (six core set variables defined in ACR PEDI outcome score) were recorded along with alkalyne DnaseI serum levels using the method where acid soluble nucleotides are determined spectrophotometrically at 260 nm. Treatment schedule of etanercept was 0, 4 mg/kg body weight subcutaneously twice weekly.

Results

JIA patients mean age was 14,7 +/- 4,22 and disease duration is 6,59 +/- 2,76. Disease type distribution was 8% systemic, 28% polyarticular RF-, 25% polyarticular RF+, 17% ERA and 21% extended oligoarticular JIA. Summary of data results prior and after anti TNFα therapy: ESR 26,88 vs. 15,52 (p < 0,01); patientVAS 40,24 vs. 24,40 (p < 0,05); physicianVAS 38,08 vs. 10,32 (p < 0,01); CHAQ 0,674 vs.0,375 (p < 0,01); LOM 15,52 vs. 11,68 (NS); AA 9,24 vs.2,64 (p < 0,01). DNaseI levels were significantly lower prior (2.934 U/l) compared to values after one year therapy (4,184 U/l; p < 0,01). We have found correlation between DNaseI levels and AA (r = -0,993 p < 0,5) and other clinical outcome variables prior and after therapy.

Conclusion

JIA patients with active disease have decreased DNase I levels. Our results indicate significant increase of DNaseI in the sera of JIA patients after one year of anti TNFα therapy which was associated to the disease clinical improvement.

Author information

Correspondence to J Vojinovic.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Etanercept
  • Type Distribution
  • Disease Type
  • Chronic Arthritis
  • Etanercept Therapy